Compare TITN & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TITN | LRMR |
|---|---|---|
| Founded | 1980 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 477.0M | 280.0M |
| IPO Year | 2007 | 2014 |
| Metric | TITN | LRMR |
|---|---|---|
| Price | $19.66 | $5.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $21.50 | $16.14 |
| AVG Volume (30 Days) | 154.2K | ★ 6.3M |
| Earning Date | 01-01-0001 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,702,122,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.50 | $1.61 |
| 52 Week High | $21.75 | $6.42 |
| Indicator | TITN | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 60.79 | 68.30 |
| Support Level | $18.60 | $3.18 |
| Resistance Level | $20.91 | $5.37 |
| Average True Range (ATR) | 1.02 | 0.46 |
| MACD | -0.04 | 0.28 |
| Stochastic Oscillator | 49.20 | 69.10 |
Titan Machinery Inc owns and operates a network of full-service agricultural and construction equipment stores. The company sells and repairs agricultural equipment, including machinery and attachments for large-scale farming and home and gardening purposes, as well as construction equipment. It operates through the following segments: The Agriculture segment sells, services, and rents machinery and related parts and attachments, for uses ranging from large-scale farming to home and garden use, The construction segment sells, services, and rents machinery, and related parts and attachments, for uses ranging from heavy construction to light industrial machinery use, and the Europe and Australia segments.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.